Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031287 | 0.89 | ADORA2A (0.64) | ADORA2AADORA1KMT2AMEN1MAPT | |
| SCHEMBL29678556 | 0.89 | ADORA2A (0.64) | ADORA2AADORA1KMT2AMEN1MAPT | |
| SCHEMBL20666178 | 0.88 | ADORA2A (0.65) | ADORA2AADORA1KMT2AMEN1USP7 | |
| SCHEMBL20658466 | 0.83 | ADORA2A (0.58) | ADORA2AADORA1KMT2AMEN1CKS1B | |
| SCHEMBL27328541 | 0.81 | KMT2A (0.59) | ADORA2AADORA1KMT2AMEN1MAPT | |
| SCHEMBL20600757 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL20658539 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL20658540 | 0.80 | ADORA2A (0.63) | ADORA2AADORA1KMT2AMEN1MAPT | |
| SCHEMBL20658472 | 0.80 | ADORA2A (0.75) | ADORA2AADORA1CKS1BSKP1SKP2 | |
| SCHEMBL20666629 | 0.80 | ADORA2A (0.63) | ADORA2AADORA1CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3654978-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | Nuvation Bio Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| CN-111163780-A | Heterocyclic compounds as adenosine antagonists | 诺维逊生物股份有限公司 | 2020-05-15 | — | — | CN | disclosed |
| WO-2019018584-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | GiraFpharma LLC (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885KMT2A 2807/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885KMT2A 2807/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885KMT2A 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.